|
Editorial Board
Editor-in-Chief
Anthony T. Campagnoni Los Angeles, U.S.A. Deputy Editor-in-Chief Reviews Editor Senior Editors |
ASN NEURO (2010) 2(4):art:e00040.doi:10.1042/AN20100015
Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice
Michael J Urban*, Chengyuan Li†, Cuijuan Yu†, Yuanming Lu*, Joanna M Krise‡, Michelle P McIntosh‡, Roger A Rajewski‡, Brian S J Blagg* and Rick T Dobrowsky†1
*Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS 66045, U.S.A.
†Department of Pharmacology and Toxicology, The University of Kansas, 5064 Malott Hall, 1251 Wescoe Hall Dr., Lawrence, KS 66045, U.S.A. ‡Biotechnology Innovation and Optimization Center, The University of Kansas, Lawrence, KS 66045, U.S.A.
Cite this article as: Michael J Urban, Chengyuan Li, Cuijuan Yu, Yuanming Lu, Joanna M Krise, Michelle P McIntosh, Roger A Rajewski, Brian S J Blagg and Rick T Dobrowsky (2010) Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice. ASN NEURO 2(4):art:e00040.doi:10.1042/AN20100015
Increasing the expression of Hsp70 (heat-shock protein 70) can inhibit sensory neuron degeneration after axotomy. Since the onset of DPN (diabetic peripheral neuropathy) is associated with the gradual decline of sensory neuron function, we evaluated whether increasing Hsp70 was sufficient to improve several indices of neuronal function. Hsp90 is the master regulator of the heat-shock response and its inhibition can up-regulate Hsp70. KU-32 (N-{7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy]-8-methyl-2-oxo-2H-chromen-3-yl}acetamide) was developed as a novel, novobiocin-based, C-terminal inhibitor of Hsp90 whose ability to increase Hsp70 expression is linked to the presence of an acetamide substitution of the prenylated benzamide moiety of novobiocin. KU-32 protected against glucose-induced death of embryonic DRG (dorsal root ganglia) neurons cultured for 3 days in vitro. Similarly, KU-32 significantly decreased neuregulin 1-induced degeneration of myelinated Schwann cell DRG neuron co-cultures prepared from WT (wild-type) mice. This protection was lost if the co-cultures were prepared from Hsp70.1 and Hsp70.3 KO (knockout) mice. KU-32 is readily bioavailable and was administered once a week for 6 weeks at a dose of 20 mg/kg to WT and Hsp70 KO mice that had been rendered diabetic with streptozotocin for 12 weeks. After 12 weeks of diabetes, both WT and Hsp70 KO mice developed deficits in NCV (nerve conduction velocity) and a sensory hypoalgesia. Although KU-32 did not improve glucose levels, HbA1c (glycated haemoglobin) or insulin levels, it reversed the NCV and sensory deficits in WT but not Hsp70 KO mice. These studies provide the first evidence that targeting molecular chaperones reverses the sensory hypoalgesia associated with DPN. Key words: diabetic neuropathy, dorsal root ganglia neuron, heat-shock protein 70, molecular chaperone, nerve conduction velocity, neurodegeneration Abbreviations: AM, acetoxymethyl ester, DAPI, 4′,6-diamidino-2-phenylindole, DMEM, Dulbecco's modified Eagle's medium, DPN, diabetic peripheral neuropathy, DRG, dorsal root ganglion, Drp1, dynamin-related protein 1, FBG, fasting blood glucose, FCS, fetal calf serum, Hsc70, heat-shock cognate 70 stress protein, HSF1, heat-shock factor 1, Hsp90, heat-shock protein 90, HSR, heat-shock response, JNK, c-Jun N-terminal kinase, KO, knockout, KU-32, N-{7-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy]-8-methyl-2-oxo-2H-chromen-3-yl}acetamide, LC-MS, liquid chromatography MS, MBP, myelin basic protein, MNCV, motor NCV, NCV, nerve conduction velocity, NGF, nerve growth factor, NRG1, human recombinant neuregulin-1-β1 epidermal growth factor domain, SC-DRG, Schwann cell DRG, SNCV, sensory NCV, STZ, streptozotocin, WT, wild-type 1To whom correspondence should be addressed (email dobrowsky@ku.edu). Received 4 June 2010/8 July 2010; accepted 14 July 2010 Published as ASN NEURO Immediate Publication 14 July 2010, doi:10.1042/AN20100015 ©2010 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence ( |
ISSN: 1759-0914
Published by Portland Press Limited on behalf of the American Society for Neurochemistry
*Publication time subject to receipt of payment
†2010 Journal Citation Reports® (Thomson Reuters, 2011) |